Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
BEAM
Beam Therapeutics Inc.
Beam's core offering is a base editing gene therapy platform (DNA editing to correct disease-causing mutations).
|
$2.78B |
$25.79
-6.01%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$2.53B |
$38.72
-2.36%
|
|
TVTX
Travere Therapeutics, Inc.
Lead product FILSPARI (sparsentan) is an oral small molecule therapeutic for IgA nephropathy, representing the core commercial and product-focused program.
|
$2.52B |
$27.57
-2.16%
|
|
APLS
Apellis Pharmaceuticals, Inc.
SYFOVRE is an ophthalmic drug (intravitreal) approved for geographic atrophy, representing a direct product Apellis sells.
|
$2.51B |
$20.16
+1.54%
|
|
ADPT
Adaptive Biotechnologies Corporation
Antibody Discovery Platform cited as part of Immune Medicine R&D capabilities.
|
$2.51B |
$15.88
-3.44%
|
|
RCUS
Arcus Biosciences, Inc.
Arcus operates in oncology with innovative IO therapies (HIF-2α inhibitor casdatifan; TIGIT antibody domvanalimab; CD73 inhibitor quemliclustat) making it a Biotech - Oncology company.
|
$2.45B |
$21.35
-5.86%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$2.35B |
$10.31
-6.61%
|
|
IRON
Disc Medicine, Inc.
Disc Medicine concentrates on rare hematologic diseases (e.g., EPP, Diamond-Blackfan anemia) by targeting iron and heme pathways, with a pipeline centered on rare-disease indications.
|
$2.31B |
$60.11
-1.62%
|
|
WGS
GeneDx Holdings Corp.
Companion diagnostics partnerships leverage genomic data to identify patients for therapies.
|
$2.30B |
$80.66
+1.49%
|
|
WVE
Wave Life Sciences Ltd.
Wave Life Sciences' core products are stereopure oligonucleotides and oligonucleotide therapeutics (antisense/siRNA/editing AIMers) used as RNA medicines.
|
$2.29B |
$13.41
-2.15%
|
|
GLPG
Galapagos N.V.
Core product category: CAR-T and other cell therapies (cell therapy platform).
|
$2.22B |
$33.45
-0.73%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$2.18B |
$14.65
-3.81%
|
|
ETNB
89bio, Inc.
Pegozafermin is a peptide-based therapeutic; directly marketed as a Peptide Therapeutics product.
|
$2.17B |
$14.85
+0.07%
|
|
ZLAB
Zai Lab Limited
Core oncology focus across a deep late-stage pipeline including multiple oncology antibodies and ADC assets.
|
$2.13B |
$19.18
-0.47%
|
|
PAHC
Phibro Animal Health Corporation
Vaccines are explicitly listed as a pillar of the Animal Health segment.
|
$2.10B |
$50.89
-1.93%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
Ultragenyx is a rare-disease focused biotech company with approved therapies and a pipeline centered on ultra-rare diseases.
|
$2.10B |
$21.53
-1.24%
|
|
AVDL
Avadel Pharmaceuticals plc
LUMRYZ is an oral small molecule therapeutic (sodium oxybate) used to treat narcolepsy; Avadel's core product.
|
$2.10B |
$21.66
+0.09%
|
|
BHC
Bausch Health Companies Inc.
Xifaxan and the RED-C program are oral small-molecule therapeutics within the Salix hepatology portfolio.
|
$2.09B |
$5.54
-1.60%
|
|
IMNM
Immunome, Inc.
Primary modality across the pipeline is Antibody-Drug Conjugates (ADCs).
|
$2.07B |
$21.26
-5.60%
|
|
SLNO
Soleno Therapeutics, Inc.
Core product category: Soleno's VYKAT XR is an oral small molecule therapeutic (diazoxide choline extended-release) targeting hyperphagia in Prader-Willi Syndrome.
|
$2.05B |
$37.48
-1.72%
|
|
MAZE
Maze Therapeutics, Inc.
Maze develops small molecule therapeutics, including MZE829 and MZE782, which are oral small molecule treatments for renal/cardiovascular/metabolic diseases.
|
$2.04B |
$45.06
-3.06%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$2.00B |
$59.79
-3.61%
|
|
AUPH
Aurinia Pharmaceuticals Inc.
LUPKYNIS (voclosporin) is an immunology/autoimmune therapy, aligning Aurinia's core business with immunology therapeutics.
|
$1.98B |
$14.70
-2.26%
|
|
CLDX
Celldex Therapeutics, Inc.
Barzolvolimab is a therapeutic monoclonal antibody, placing Celldex in Monoclonal Antibody Therapeutics.
|
$1.96B |
$29.21
-1.12%
|
|
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma is a biotech company focused on oncology, developing apoptosis-targeted cancer therapies (olverembatinib, lisaftoclax, alrizomadlin).
|
$1.94B |
$21.68
-2.58%
|
|
MLYS
Mineralys Therapeutics, Inc.
The company is pursuing a cardiovascular hypertension therapy, placing Mineralys under the Cardiovascular Drugs category.
|
$1.91B |
$26.95
-6.31%
|
|
RXRX
Recursion Pharmaceuticals, Inc.
Collaborations with pharma partners and outsourced discovery work resemble a CRO-type service model.
|
$1.90B |
$3.50
-3.71%
|
|
ZYME
Zymeworks Inc.
Lead ADC programs leverage proprietary antibody-drug conjugate platforms with a defined payload.
|
$1.89B |
$24.63
-2.38%
|
Showing page 6 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
